Will the CSL share price crack the $300 barrier this week?

The CSL Limited (ASX: CSL) share price could break the $300 barrier this week – is there still time to buy the healthcare group for growth?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has started the new decade exactly how it finished the last – rocketing higher.

The healthcare group's shares closed at $299.30 per share last Friday and set a new all-time high in the process.

a woman

Why you should watch the CSL share price this week

There's a good chance the CSL share price could finally breach the $300 per share barrier for the first time ever.

That would be an impressive start to the new year, given the healthcare group's shares are up a whopping 38,973% since its IPO.

CSL listed on the ASX in 1994 for an adjusted 3-for-1 stock split price of just 76.6 cents per share. That means an investor who bought and held $10,000 worth of CSL shares since the IPO would be sitting on $3,897,310.70 today.

Of course, most investors would have sold their shares well short of today's all-time high. But if you were a true long-term buy-and-hold investor, that is a very tidy return from the CSL share price.

Where can I find the next CSL?

That is the multi-million-dollar question everyone would love an answer to. There have been several strong ASX growth shares emerge in recent years, all of which have potential.

The most notable ones are the "WAAAX" tech shares including Altium Limited (ASX: ALU), Appen Ltd (ASX: APX) and Xero Limited (ASX: XRO), which have seen similar growth trajectories to the CSL share price.

Outside of these, Nearmap Ltd (ASX: NEA) shares have rocketed higher in the past decade, and it has been a similar story for buy-now, pay-later companies like Zip Co Ltd (ASX: Z1P) and Afterpay Ltd (ASX: APT).

How can I make huge returns on the ASX?

To make the really big money and cash in on share price rises like CSL, you really have to be an IPO investor.

That is more difficult than you think, with evidence showing that you're likely to lose money by investing in IPOs in the long-term.

Of course, if you can ride a winner like CSL all the way to the top, you may only need one ASX growth stock to make your retirement plans a reality.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO, CSL Ltd., and ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. The Motley Fool Australia owns shares of Altium and Xero. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »